Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases

View/ Open
Date
2011-07-06Author
Kanaan, Nicholas M.
Concept link
Morfini, Gerardo A.
Concept link
LaPointe, Nichole E.
Concept link
Pigino, Gustavo F.
Concept link
Patterson, Kristina R.
Concept link
Song, Yuyu
Concept link
Andreadis, Athena
Concept link
Fu, Yifan
Concept link
Brady, Scott T.
Concept link
Binder, Lester I.
Concept link
Metadata
Show full item recordCitable URI
https://hdl.handle.net/1912/4666As published
https://doi.org/10.1523/JNEUROSCI.0560-11.2011DOI
10.1523/JNEUROSCI.0560-11.2011Abstract
Aggregated filamentous forms of hyperphosphorylated tau (a microtubule-associated protein) represent pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. While axonal transport dysfunction is thought to represent a primary pathogenic factor in AD and other neurodegenerative diseases, the direct molecular link between pathogenic forms of tau and deficits in axonal transport remain unclear. Recently, we demonstrated that filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Here, we demonstrate that amino acids 2–18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway in axoplasms isolated from squid giant axons. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Importantly, immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity, an early marker of pathological tau. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT. Results from these studies reveal a novel role for tau in modulating axonal phosphotransferases and provide a molecular basis for a toxic gain-of-function associated with pathogenic forms of tau.
Description
© The Author(s), 2011. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Journal of Neuroscience 31 (2011): 9858-9868, doi:10.1523/JNEUROSCI.0560-11.2011.
Collections
Suggested Citation
Journal of Neuroscience 31 (2011): 9858-9868The following license files are associated with this item: